Daily Broadcaster

Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight

 Breaking News
  • No posts were found

Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight

September 17
19:08 2021
Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight
Chemotherapy-Induced Diarrhea Pipeline

DelveInsight’s Chemotherapy-induced Diarrhea Pipeline Insights report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents. 

The Chemotherapy-induced Diarrhea Pipeline report provides a comprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.

 

Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:

  • The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.
  • Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420, Mytesi, OQL051, DP 1038 and others. 
  • Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals, among others.

 

Request for Sample report to discover more about the therapies set to grab maximum patient pool @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

 

Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan. 

 

Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants

Drug

Company

Phase

MoA

RoA

FW-420

AzuRx BioPharma

Unknown

MTOR protein inhibitors

Oral/rectal

Mytesi

Napo Pharmaceuticals

Phase III

Chloride channel antagonists

Oral

OQL051

OnQuality Pharmaceuticals

Discovery

NA

NA

DP 1038

Dauntless Pharmaceuticals

Phase II

Growth hormone-releasing hormone inhibitors;

Somatostatin receptor agonists

Intranasal

 

Chemotherapy-induced Diarrhea Therapeutic Assessment

The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

 

Scope of the Report Coverage: Global Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others.  Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others. 

 

Reach out @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

 

Table of Contents 

1

Report Introduction

2

Chemotherapy-induced Diarrhea Disease Overview

3

Chemotherapy-induced Diarrhea Pipeline Outlook

4

Comparative Analysis

5

Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage

6

Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage

7

Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis

8

Inactive Chemotherapy-induced Diarrhea Pipeline Products 

9

Appendix

10

Report Methodology

11

Consulting Services

12

Disclaimer

13

About DelveInsight

Visit to know more of what’s covered @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-pipeline-insights

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-diarrhea-pipeline-insights